Merck's stock has formed a double top pattern with a breakdown below the $112.72 neckline, indicating rising bearish pressure and a potential deeper correction. Key resistance levels near $117.36 and $115.72 could limit any short-term rallies. A sustained move above $119.36 is needed to negate the bearish outlook; otherwise, the stock may test lower support levels. Despite this correction risk, Merck's long-term uptrend remains intact, leaving room for a possible bullish recovery if new highs are reached.
Retirees with $500,000 to invest in dividend ETFs face a choice between Vanguard Dividend Appreciation ETF (VIG) and Schwab U.S. Dividend Equity ETF (SCHD). VIG offers lower current yield (~1.7%-1.8%) but focuses on companies with long histories of d...
Healthcare mergers and acquisitions surged to $65 billion in the first quarter of 2026, the highest since 2020, fueled by looming patent expirations on blockbuster drugs like Merck’s Keytruda. Pharma companies are acquiring innovative biotech firms t...
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
